Top

Published in:

01-04-2013 | Head and Neck Cancers (EY Hanna, Section Editor)

Transoral Microsurgery for Treatment of Laryngeal and Pharyngeal Cancers

Authors: Carlos Suárez, Juan P. Rodrigo

Published in: Current Oncology Reports | Issue 2/2013

Abstract

Minimally invasive surgery has evolved over the last two decades to encompass all fields of surgery, including curative intent cancer surgery of the head and neck. Much evidence is in favor of routine use of transoral laser resection, which can be considered the method of choice for treatment of early laryngeal carcinomas (T1–T2) of the glottis and the supraglottis on the basis of oncologic, functional, and cost considerations. The results of transoral laser microsurgery in patients with moderately advanced (T3) supraglottic cancer are comparable to those of open supraglottic laryngectomy with regard to local control and survival rates, and they are superior to those of primary radiotherapy with respect to organ preservation. Transoral laser microsurgery as a unique treatment should also be considered as an alternative to other organ preservation protocols in the early stages (I–II) of hypopharyngeal and oropharyngeal carcinomas.

Karatzanis AD, Waldfahrer F, Psychogios G, et al. Resection margins and other prognostic factors regarding surgically treated glottic carcinomas. J Surg Oncol. 2010;101:131–6.PubMed

Ansarin M, Santoro L, Cattaneo A, et al. Laser surgery for early glottic cancer: impact of margin status on local control and organ preservation. Arch Otolaryngol Head Neck Surg. 2009;135:385–90.PubMedCrossRef

Blanch JL, Vilaseca I, Bernal-Sprekelsen M, et al. Prognostic significance of surgical margins in transoral CO(2) laser microsurgery for T1-T4 pharyngo-laryngeal cancers. Eur Arch Otorhinolaryngol. 2007;264:1045–51.PubMedCrossRef

Jackel MC, Ambrosch P, Martin A, Steiner W. Impact of re-resection for inadequate margins on the prognosis of upper aerodigestive tract cancer treated by laser microsurgery. Laryngoscope. 2007;117:350–6.PubMedCrossRef

Michel J, Fakhry N, Duflo S, et al. Prognostic value of the status of resection margins after endoscopic laser cordectomy for T1a glottic carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:297–300.PubMedCrossRef

Hartl DM, de Monès E, Hans S, et al. Treatment of early-stage glottic cancer by transoral laser resection. Ann Otol Rhinol Laryngol. 2007;116:832–6.PubMed

Lucioni M, Marioni G, Bertolin A, et al. Glottic laser surgery: outcomes according to 2007 ELS classification. Eur Arch Otorhinolaryngol. 2011;268:1771–8.PubMedCrossRef

Jeong WJ, Kim H, Ahn JC, et al. Serial endoscopic analysis of the glottis following laser cordectomy: from an oncological perspective. Lasers Med Sci. 2012;27:1025–31.PubMedCrossRef

Just T, Lankenau E, Prall F, et al. Optical coherence tomography allows for the reliable identification of laryngeal epithelial dysplasia and for precise biopsy: a clinicopathological study of 61 patients undergoing microlaryngoscopy. Laryngoscope. 2010;120:1964–70.PubMedCrossRef

10.

Pogorzelski B, Hanenkamp U, Goetz M, et al. Systematic intraoperative application of confocal endomicroscopy for early detection and resection of squamous cell carcinoma of the head and neck: a preliminary report. Arch Otolaryngol Head Neck Surg. 2012;138:404–11.PubMedCrossRef

11.

Verma SP, Dailey SH. Overcoming nasal discomfort—a novel method for office-based laser surgery. Laryngoscope. 2011;121:2396–8.PubMedCrossRef

12.

• Peretti G, Piazza C, Cocco D, et al. Transoral CO(2) laser treatment for T(is)-T(3) glottic cancer: the University of Brescia experience on 595 patients. Head Neck. 2010;32:977–83. This provides a clear presentation of results by T stage in an important series. PubMedCrossRef

13.

Vilaseca I, Bernal-Sprekelsen M, Blanch JL. Transoral laser microsurgery for T3 laryngeal tumors: Prognostic factors. Head Neck. 2010;32:929–38.PubMed

14.

López-Álvarez F, Rodrigo JP, Llorente-Pendás JL, Suárez-Nieto C. Transoral laser microsurgery in advanced carcinomas of larynx and pharynx. Acta Otorrinolaringol Esp. 2011;62:95–102.PubMedCrossRef

15.

Blanch JL, Vilaseca I, Caballero M, et al. Outcome of transoral laser microsurgery for T2-T3 tumors growing in the laryngeal anterior commissure. Head Neck. 2011;33:1252–9.PubMedCrossRef

16.

Olthoff A, Ewen A, Wolff HA, et al. Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer. Strahlenther Onkol. 2009;185:303–9.PubMedCrossRef

17.

Hinni ML, Salassa JR, Grant DG, et al. Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007;133:1198–204.PubMedCrossRef

18.

Roedel RM, Matthias C, Wolff HA, et al. Transoral laser microsurgery for recurrence after primary radiotherapy of early glottic cancer. Auris Nasus Larynx. 2010;37:474–81.PubMedCrossRef

19.

Han YJ, Lee HS, Kim SW, et al. Transoral laser microsurgery of recurrent early glottic cancer after radiation therapy: clinical feasibility and limitations. Ann Otol Rhinol Laryngol. 2012;121:375–82.PubMed

20.

Schrijvers ML, van Riel EL, Langendijk JA, et al. Higher laryngeal preservation rate after CO2 laser surgery compared with radiotherapy in T1a glottic laryngeal carcinoma. Head Neck. 2009;31:759–64.PubMedCrossRef

21.

• Higgins KM, Shah MD, Ogaick MJ, Enepekides D. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg. 2009;38:603–12. This is as meta-analysis of oncologic and functional outcomes. PubMed

22.

Feng Y, Wang B, Wen S. Laser surgery versus radiotherapy for T1–N0 glottic cancer: a meta-analysis. ORL J Otorhinolaryngol Relat Spec. 2011;73:336–42.PubMedCrossRef

23.

Viani L, Stell PM, Dalby JE. Recurrence after radiotherapy for glottic carcinoma. Cancer. 1991;67:577–84.PubMedCrossRef

24.

Eckel HE. Endoscopic laser resection of supraglottic carcinoma. Otolaryngol Head Neck Surg. 1997;117:681–7.PubMedCrossRef

25.

Preuss SF, Cramer K, Klussmann JP, et al. Transoral laser surgery for laryngeal cancer: outcome, complications and prognostic factors in 275 patients. Eur J Surg Oncol. 2009;35:235–40.PubMedCrossRef

26.

Phillips TJ, Sader C, Brown T, et al. Transoral laser microsurgery versus radiation therapy for early glottic cancer in Canada: cost analysis. J Otolaryngol Head Neck Surg. 2009;38:619–23.PubMed

27.

•• Higgins KM. What treatment for early-stage glottic carcinoma among adult patients: CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is superior in terms of cost utility? Laryngoscope. 2011;121:116–34. This is an extremely well conducted meta-analysis of costs and outcomes. PubMedCrossRef

28.

Merrot O, Bige V, Poupart M, et al. Comparison between external radiotherapy and laser microsurgery for the treatment of TisT1N0 glottic carcinoma: Clinical modelling and cost-minimization study from the French national health insurance payer's point of view. Rev Laryngol Otol Rhinol (Bord). 2010;131:257–62.

29.

Sjögren EV, van Rossum MA, Langeveld TP, et al. Voice outcome in T1a midcord glottic carcinoma: laser surgery vs radiotherapy. Arch Otolaryngol Head Neck Surg. 2008;134:965–72.PubMedCrossRef

30.

Núñez Batalla F, Caminero Cueva MJ, Señaris González B, et al. Voice quality after endoscopic laser surgery and radiotherapy for early glottic cancer: objective measurements emphasizing the Voice Handicap Index. Eur Arch Otorhinolaryngol. 2008;265:543–8.PubMedCrossRef

31.

Osborn HA, Hu A, Venkatesan V, et al. Comparison of endoscopic laser resection versus radiation therapy for the treatment of early glottic carcinoma. J Otolaryngol Head Neck Surg. 2011;40:200–4.PubMed

32.

Dinapoli N, Parrilla C, Galli J, et al. Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population. Strahlenther Onkol. 2010;186:607–13.PubMedCrossRef

33.

• Spielmann PM, Majumdar S, Morton RP. Quality of life and functional outcomes in the management of early glottis carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery. Clin Otolaryngol. 2010;35:373–82. This is a comprehensive systematic review analyzing vocal outcomes. PubMedCrossRef

34.

Suárez C, Rodrigo JP, Silver CE, et al. Laser surgery for early to moderately advanced Glottic. Supraglottic and Hypopharyngeal Cancers. Head Neck. 2012;34:1028–35.PubMedCrossRef

35.

Rudert HH, Werner JA, Höft S. Transoral carbon dioxide laser resection of supraglottic carcinoma. Ann Otol Rhinol Laryngol. 1999;108:819–27.PubMed

36.

Ambrosch P, Kron M, Steiner W. Carbon dioxide laser microsurgery for early supraglottic carcinoma. Ann Otol Rhinol Laryngol. 1998;107:680–8.PubMed

37.

Motta G, Esposito E, Testa D, et al. CO2 laser treatment of supraglottic cancer. Head Neck. 2004;26:442–6.PubMedCrossRef

38.

González-Márquez R, Rodrigo JP, Llorente JL, et al. Transoral CO₂ laser surgery for supraglottic cancer. Eur Arch Otorhinolaryngol. 2012;269:2081–6.PubMedCrossRef

39.

Cabanillas R, Rodrigo JP, Llorente JL, Suárez C. Oncologic outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach. Head Neck. 2008;30:750–5.PubMedCrossRef

40.

Bussu F, Almadori G, De Corso E, et al. Endoscopic horizontal partial laryngectomy by CO(2) laser in the management of supraglottic squamous cell carcinoma. Head Neck. 2009;31:1196–206.PubMedCrossRef

41.

Roh JL, Kim DH, Park CI. Voice, swallowing and quality of life in patients after transoral laser surgery for supraglottic carcinoma. J Surg Oncol. 2008;98:184–9.PubMedCrossRef

42.

Cabanillas R, Rodrigo JP, Llorente JL, et al. Functional outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach. Head Neck. 2004;26:653–9.PubMedCrossRef

43.

Peretti G, Piazza C, Cattaneo A, et al. Comparison of functional outcomes after endoscopic versus open-neck supraglottic laryngectomies. Ann Otol Rhinol Laryngol. 2006;115:827–32.PubMed

44.

Rodrigo JP, Suárez C, Silver CE, et al. Transoral laser surgery for supraglottic cancer. Head Neck. 2008;30:658–66.PubMedCrossRef

45.

Vilaseca I, Blanch JL, Bernal-Sprekelsen M. Transoral laser surgery for hypopharyngeal carcinomas. Curr Opin Otolaryngol Head Neck Surg. 2012;20:97–102.PubMedCrossRef

46.

Lefebvre JL. What is the role of primary surgery in the treatment of laryngeal and hypopharyngeal cancer? Hayes Martin lecture. Arch Otolaryngol Head Neck Surg. 2000;126:285–8.PubMed

47.

Rudert HH, Höft S. Transoral carbon-dioxide laser resection of hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2003;260:198–206.PubMed

48.

Kutter J, Lang F, Monnier P, Pasche P. Transoral laser surgery for pharyngeal and pharyngolaryngeal carcinomas. Arch Otolaryngol Head Neck Surg. 2007;133:139–44.PubMedCrossRef

49.

Karatzanis AD, Psychogios G, Waldfahrer F, et al. T1 and T2 hypopharyngeal cancer treatment with laser microsurgery. J Surg Oncol. 2010;102:27–33.PubMedCrossRef

50.

Vilaseca I, Blanch JL, Bernal-Sprekelsen M, Moragas M. CO2 laser surgery: a larynx preservation alternative for selected hypopharyngeal carcinomas. Head Neck. 2004;26:953–9.PubMedCrossRef

51.

Martin A, Jäckel MC, Christiansen H, et al. Organ preserving transoral laser microsurgery for cancer of the hypopharynx. Laryngoscope. 2008;118:398–402.PubMedCrossRef

52.

Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94:2967–80.PubMedCrossRef

53.

Eckel HE, Volling P, Pototschnig C, et al. Transoral laser resection with staged discontinuous neck dissection for oral cavity and oropharynx squamous cell carcinoma. Laryngoscope. 1995;105:53–60.PubMedCrossRef

54.

Steiner W, Fierek O, Ambrosch P, et al. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg. 2003;129:36–43.PubMedCrossRef

55.

Grant DG, Salassa Jr, Hinni ML, et al. Carcinoma of the tongue base treated by transoral laser microsurgery, part one: untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006;116:2150–2155.

56.

Camp AA, Fundakowski C, Petruzzelli GJ, et al. Functional and oncologic results following transoral laser microsurgical excision of base of tongue carcinoma. Otolaryngol Head Neck Surg. 2009;141:66–9.PubMedCrossRef

57.

Henstrom DK, Moore EJ, Olsen KD, et al. Transoral resection for squamous cell carcinoma of the base of tongue. Arch Otolaryngol Head Neck Surg. 2009;135:1231–8.PubMedCrossRef

58.

Rich JT, Milov S, Lewis Jr JS, et al. Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope. 2009;119:1709–19.PubMedCrossRef

59.

• Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33:1683–94. This multicenter study demonstrated the feasibility of TLM as a valid alternative to chemoradiotherapy in advanced oropharyngeal carcinoma. PubMedCrossRef

60.

Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.PubMedCrossRef

61.

Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24:593–8.PubMedCrossRef

62.

León X, López M, García J, Quer M. Results of an organ conservation protocol in patients with locally advanced laryngeal tumours. Acta Otorrinolaringol Esp. 2009;60:176–85.PubMedCrossRef

63.

Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.PubMedCrossRef

64.

Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1–N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19:4029–36.PubMed

65.

Chera BS, Amdur RJ, Morris CG, et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78:461–6.PubMedCrossRef

66.

Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41:347–53.PubMedCrossRef

67.

Nakfoor BM, Spiro IJ, Wang CC, et al. Results of accelerated radiotherapy for supraglottic carcinoma: a Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary experience. Head Neck. 1998;20:379–84.PubMedCrossRef

68.

Mahler V, Boysen M, Brøndbo K. Radiotherapy or CO(2) laser surgery as treatment of T(1a) glottic carcinoma? Eur Arch Otorhinolaryngol. 2010;267:743–50.PubMedCrossRef

Title: Transoral Microsurgery for Treatment of Laryngeal and Pharyngeal Cancers
Authors: Carlos Suárez
Juan P. Rodrigo
Publication date: 01-04-2013
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 2/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-012-0286-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Regorafenib (BAY 73–4506): Stromal and Oncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma

Pathological Complete Response After Neoadjuvant Therapy for Rectal Cancer and the Role of Adjuvant Therapy

Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer

Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer: An Emerging Paradigm?

Anal Cancer: Are We Making Progress?

Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer